--- title: "GlucoTrack | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286471779.md" datetime: "2026-05-14T21:29:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286471779.md) - [en](https://longbridge.com/en/news/286471779.md) - [zh-HK](https://longbridge.com/zh-HK/news/286471779.md) --- # GlucoTrack | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -2.65. EBIT: As of FY2026 Q1, the actual value is USD -4.203 M. ### Segment Information GlucoTrack, Inc. operates as a single reportable segment, the Glucotrack CBGM Product Segment, focusing all its research and development activities on this product. ### Financial Performance #### Net Loss Net loss for the three months ended March 31, 2026, was - $4,334 thousand, a decrease compared to a net loss of - $6,833 thousand for the same period in 2025. This reduction was primarily attributed to a decrease in other expense. #### Operating Expenses - **Research and Development (R&D) Expenses**: R&D expenses were - $2,132 thousand for the three months ended March 31, 2026, an increase of - $261 thousand from - $1,871 thousand in the prior-year period, primarily due to higher expenses for product design, development, manufacturing, and pre-clinical animal studies. - **General and Administrative (G&A) Expenses**: G&A expenses totaled - $2,071 thousand for the three months ended March 31, 2026, an increase of - $444 thousand from - $1,627 thousand in the prior-year period, mainly due to increased professional fees and personnel costs. - **Total Operating Expenses**: Total operating expenses were - $4,203 thousand for the three months ended March 31, 2026, compared to - $3,498 thousand for the three months ended March 31, 2025. - **Loss from Operations**: Loss from operations was - $4,203 thousand for the three months ended March 31, 2026, compared to - $3,498 thousand for the same period in 2025. #### Other (Income) Expense, net Other expense was - $131 thousand for the three months ended March 31, 2026, a significant decrease from - $3,335 thousand in the prior-year period, primarily due to a reduction in the change of derivative liabilities. #### Comprehensive Loss Comprehensive loss for the period was - $4,331 thousand for the three months ended March 31, 2026, compared to - $6,797 thousand for the same period in 2025. ### Cash Flow #### Cash and Cash Equivalents As of March 31, 2026, cash and cash equivalents were - $3,929 thousand, down from - $7,383 thousand as of December 31, 2025. #### Operating Activities Net cash used in operating activities was - $4,048 thousand for the three months ended March 31, 2026, compared to - $2,939 thousand for the same period in 2025. #### Investing Activities Net cash used in investing activities was - $0 thousand for the three months ended March 31, 2026, compared to - $9 thousand for the same period in 2025. #### Financing Activities Net cash provided by financing activities was - $591 thousand for the three months ended March 31, 2026, primarily from the exercise of pre-funded warrants (- $1 thousand) and ELOC financing (- $590 thousand). This compares to - $6,395 thousand in net cash provided by financing activities for the same period in 2025, mainly from underwritten U.S. public offerings. ### Other Key Financial Metrics #### Accumulated Deficit As of March 31, 2026, the company had an accumulated deficit of - $156,172 thousand. #### Promissory Notes Promissory notes amounted to - $3,330 thousand as of March 31, 2026, up from - $3,182 thousand as of December 31, 2025. During the three months ended March 31, 2026, - $148 thousand of the original issue discount related to a promissory note was amortized to interest expense. #### Derivative Financial Liabilities Derivative financial liabilities were - $0 thousand as of March 31, 2026, down from - $1 thousand as of December 31, 2025. ### Future Outlook and Strategy #### Core Business Focus GlucoTrack, Inc. is focused on developing the Glucotrack CBGM for Type 1 and insulin-dependent Type 2 diabetes patients. The company has submitted an Investigational Device Exemption (IDE) application to the U.S. FDA to initiate a U.S. clinical study and expects R&D expenses to increase in 2026 and beyond due to expanding clinical trial activities, hiring additional personnel, and developing the Glucotrack CBGM. #### Liquidity and Going Concern The company has a history of recurring losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, as current cash and cash equivalents are not expected to fund operating cash flow needs for the next twelve months. GlucoTrack, Inc. plans to finance operations through additional capital raised via debt financings, private or public equity financings, license agreements, collaborative agreements, or other arrangements. #### Nasdaq Listing Status On May 11, 2026, GlucoTrack, Inc. received a Staff Determination letter from Nasdaq indicating its common stock would be delisted due to not meeting the minimum $1.00 bid price requirement. The company intends to appeal this determination and will consider options to regain compliance, including potentially implementing a reverse stock split, while also facing a proposed new Nasdaq rule requiring a minimum $5 million market value of listed securities. ### Related Stocks - [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md) ## Related News & Research - [Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | GCTK Stock News](https://longbridge.com/en/news/286471959.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md)